您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Oleyloxyethyl Phosphorylcholine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Oleyloxyethyl Phosphorylcholine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Oleyloxyethyl Phosphorylcholine图片
CAS NO:84601-19-4
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品介绍
Cas No.84601-19-4
别名磷酰胆碱
化学名1-O-9Z-octadecenylethyleneglycol-2-O-phosphorylcholine
Canonical SMILESCCCCCCCC/C=C\CCCCCCCCOCCOP([O-])(OCC[N+](C)(C)C)=O
分子式C25H52NO5P
分子量477.7
溶解度≤16mg/ml in DMSO;16mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 6.2 μM for porcine pancreatic PLA2

Oleyloxyethyl phosphorylcholine is a PLA2 inhibitor.

Phospholipases A2 (PLA2s) are enzymes releasing fatty acids from glycerol. This particular phospholipase can specifically recognize the sn-2 acyl bond of phospholipids and catalytically hydrolyze the bond releasing arachidonic acid and lysophosphatidic acid. Upon downstream modification by cyclooxygenases, arachidonic acid is modified into active eicosanoids, which are categorized as anti-inflammatory and inflammatory mediators.

In vitro: To examine the phospholipids including oleyloxyethyl phosphorylcholine as PLA2 inhibitors, the enzyme assay was employed. Determinations were performed below critical micelle concentration. Porcine pancreatic PLA2 and phospholipid inhibitor were preincubated for 2 min at 37℃ in buffer at pH 8.5. Introduction of [l4C]arachidonate phosphatidylcholine initiated the enzymatic reaction, which is quenched after 5 min at 37℃. In this manner 50% inhibitor concentrations were determined for mepacrine and alkylphosphorylcholines, indicating oleyloxyethyl phosphorylcholine was an inhibitor of PLA2 with an IC50 of 6.2 μM for porcine pancreatic PLA2 [1].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Magolda, R. L.,Ripka, W.C.,Galbraith, W., et al. Novel synthesis of potent site-specific phospholipase A2 inhibitors. Book: Prostaglandins, Leukotrienes and Lipoxins 669-676 (1985).